We found that prior to CD33+ cell depletion, recombinant IFN-α and IFN-β (rIFNs) fails to improve the ability of CD8+ T cells and NK cells from AML patients to respond to PMA plus ionomycin with IFN-γ synthesis and degranulation (Supplemental Fig. 6D, E). The gene discussed is IFNA2; the disease is acute myeloid leukemia.